Repair Biotechnologies Announces 48% Reversal of Atherosclerotic Plaque Lipids in a Preclinical Mouse Study
BOSTON, M.A.–Repair Biotechnologies, Inc. announced today breakthrough results from a preclinical study of the Cholesterol Degrading Platform (CDP) in a mouse model of late-stage cardiovascular disease. A single treatment of the CDP drug developed by Repair Biotechnologies resulted in a 48% reversal of the obstruction of aortic blood vessels by lipid-based plaque. Additionally, Repair Biotechnologies […]
